UBS says Lilly obesity data support pipeline beyond tirzepatide
The analyst note frames recent readouts as strengthening Eli Lilly's broader obesity portfolio rather than resting on Zepbound and Mounjaro alone.
TR
By Tom Reyes · Markets Editor
Oct 1 12:29 ETSource: Yahoo Finance
The wire
- 01UBS told clients that Eli Lilly's obesity data support a broader portfolio beyond tirzepatide, per Yahoo Finance.
- 02Incretin pipeline breadth matters to prescribers and operators planning for orforglipron and next-generation agents alongside existing tirzepatide supply.
- 03This is analyst commentary rather than a company event or new trial readout, and specific endpoints behind the view are not given here.
From the source
Read at finance.yahoo.comEli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says
